PENG Block vs Sciatico Femoral Block in the Incidence of Post Amputation Syndroms
Peri Capsular Nerve Group Block Versus Sciatico Femoral Block to Assess the Incidence of Post Amputation Syndroms in Patients Undergoing Above Knee Amputation Surgeries
1 other identifier
interventional
60
1 country
1
Brief Summary
assess the effectiveness of peri-capsular nerve group block and scaitico femoral block in the incidence of post amputation syndrome in patients undergoing above knee amputation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Jun 2023
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 7, 2023
CompletedFirst Posted
Study publicly available on registry
April 19, 2023
CompletedStudy Start
First participant enrolled
June 10, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 20, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
September 20, 2023
CompletedJuly 7, 2023
July 1, 2023
3 months
March 7, 2023
July 5, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of the efficacy of peri capsular nerve group block
Incidence of the efficacy of peri capsular nerve group block in reducing the post amputation limb pain for 24h and to compare it with the efficacy of scaitico femoral nerve block in reducing the post amputation limb pain as well.
24 hours postoperatively
Study Arms (2)
PENG group
ACTIVE COMPARATORscaitico femoral block group
ACTIVE COMPARATORInterventions
The block will be administered under ultrasound guidance with low frequency curvilinear probe. The probe will be placed parallel to the inguinal crease, at the level of anterior superior iliac spine. The scanning will be done with gradual caudad movement of the probe. After the anterior inferior iliac spine (AIIS) become visible, the probe will be turned slightly medial until the hyperechoic continuous shadow of superior pubic ramus become visible. The psoas muscle with prominent tendon will be identified just above the pubic ramus. The target is the plane between these two structures. Aligning the pubic ramus in the center of the image and targeting the pubic ramus just medial to the AIIS, a standard 25G Quincke needle will be introduced and 20 mL 0.125% bupivacaine with 4 mg dexamethasone was administered using ultrasound-guided out-of-plane technique.
. After draping the left inguinal region, the femoral nerve will be identified lateral to the femoral artery using a 5- to 13-MHz linear phased array transducer ). Under ultrasound guidance, a 25G Quincke needle will be introduced toward the femoral nerve parallel to the ultrasound beam, and 20 mL of a local anesthetic mixture 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be injected. The trajectory of the needle was adjusted to achieve even distribution of the local anesthetics around the femoral nerve. Then, the patient will be placed in the right lateral position with the left hip and knee joints flexed by 30° to 50°. Following the identification of the left sciatic nerve located in the intermuscular plane of the gluteus maximus and medius muscles between the ipsilateral ischial tuberosity and greater trochanter using a convex phased array transducer 20 mL 0.125% bupivacaine with 4 mg dexamethasone will be placed near the sciatic nerve through the 22-ga Tuohy needle
Eligibility Criteria
You may qualify if:
- ASA class I and II
- Age above 20 and less than 60 years.
- Patients undergoing above knee amputation due to any type of cancer
You may not qualify if:
- Patient refusal.
- Local infection at the puncture site.
- Coagulopathy.
- Cognitive disorders.
- Unstable cardiovascular disease.
- History of psychiatric disorders.
- History of drug abuse.
- Patients allergic to medication used.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Ahmed Ibrahim Hussien Hussien
Cairo, 11511, Egypt
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Resident of Anesthesia, Surgical Intensive Care and Pain Medicine
Study Record Dates
First Submitted
March 7, 2023
First Posted
April 19, 2023
Study Start
June 10, 2023
Primary Completion
September 20, 2023
Study Completion
September 20, 2023
Last Updated
July 7, 2023
Record last verified: 2023-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- One year
The data will be available upon reasonable request from the principal investigator